Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light therapy shows promise for ataxia symptoms in early trial

NCT ID NCT07296068

Symptom relief Sponsor: University of Central Lancashire Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether shining red and near-infrared light on the scalp (photobiomodulation) can temporarily improve balance and cognitive function in 20 adults with ataxia. Participants will receive either active light or a sham device in a randomized, placebo-controlled design. The goal is to see if this safe, non-invasive approach is worth studying further for symptom relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Photobiomodulation (light therapy)
What this could lead to
If it works, this could point toward a safe, non-drug way to temporarily improve balance and concentration in people with ataxia.
What could go wrong
This is a very small pilot study (20 people) testing only immediate effects. It may show no benefit, and any improvements might not last or apply to everyone with ataxia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-70 years (inclusive) * Diagnosis of ataxia * Able to walk independently for at least 5 minutes, with or without an assistive device * Able to stand safely for balance testing, with or without an assistive device * Hemodynamically stable (stable blood pressure and heart rate at rest) * On a stable medication regimen for ≥4 weeks prior to enrolment * Sufficient vision and hearing (with usual aids if required) to complete balance and cognitive assessments * Able to complete study questionnaires and cognitive tasks (with assistance for reading/writing if required) * Able and willing to provide written informed consent Exclusion Criteria: * Current or past history of head injury * Use of medications acting on the central nervous system * Active skin conditions on the forehead or scalp * Any other major neurological disorder that could independently affect balance or cognition * Ongoing brain stimulation therapy * History of migraines * Sensitive skin, allergies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ataxia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ataxia cerebellar ataxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ataxia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Central Lancashire

    Preston, Lancashire, PR1 2HE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.